title: New Zealand women's experience during their first year of Jadelle® contraceptive implant.
abstract: INTRODUCTION Subsidisation of the levonorgestrel-releasing Jadelle® contraceptive implant in 2010 resulted in a rapid uptake. Clinicians had little prior experience of client satisfaction, side effect profile, and removal rate of this contraceptive method. AIM To obtain information on satisfaction, bleeding patterns, continuation rates and reasons for removal for New Zealand women during their first year of use of a subsidised contraceptive implant, Jadelle®. METHODS Women having a Jadelle® implant inserted in New Zealand Family Planning clinics were recruited to be followed up by phone, text or email at 1, 3, 6, 9 and 12 months. They were asked about their bleeding pattern, satisfaction and their views on benefits of, or problems with, implant use. RESULTS 252 women were recruited. The three common bleeding patterns in the cohort were regular periods, amenorrhoea and irregular bleeding. Eighteen percent had their implant removed within the first year with more than half of those being unhappy with their bleeding pattern. This was usually prolonged bleeding. Otherwise satisfaction rates were high throughout the year. DISCUSSION The majority of New Zealand women using Jadelle® were satisfied with this method of contraception during their first year of use. Implant removals were most likely to be related to prolonged bleeding. However the commonest bleeding pattern was regular periods. KEYWORDS Contraceptive implant; progestin; bleeding; satisfaction; continuation rate; reducing reproductive health inequalities.
authors.affiliation: National Medical Advisor, Family Planning, Auckland, New Zealand. Email: christine.roke@familyplanning.org.nz.
authors.forename: Christine
authors.initials: C
authors.lastname: Roke
authors.affiliation: Associate Professor, Women's Health, Faculty of Medical and Health Sciences, University of Auckland, New Zealand.
authors.forename: Helen
authors.initials: H
authors.lastname: Roberts
authors.affiliation: Locality Medical Advisor, Family Planning, Hamilton, New Zealand.
authors.forename: Anna
authors.initials: A
authors.lastname: Whitehead
mesh_terms: D000293:Adolescent; D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004343:Drug Implants; D005006:Ethnicity / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D016912:Levonorgestrel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008483:Medical Assistance; D008875:Middle Aged; D009520:New Zealand; D017060:Patient Satisfaction; D014592:Uterine Hemorrhage / Q000139:chemically induced; D055815:Young Adult
chemical_list: D003271:Contraceptive Agents, Female; D004343:Drug Implants; D016912:Levonorgestrel